It was recently suggested that sitagliptin, via GLP-1 stabilization, is able to promote cardioprotection in a model of type 2 diabetic by reducing and limiting hyperglycemia and hyperlipidemia, as well as by promotion of survival and antihypertrophic/fibrotic effects on cultured cardiac cells, via GLP-1 and GLP-1(9-36), suggesting cell-autonomous cardioprotective actions [55]. This evidence concerns the gene GLP1R and hyperlipidemia.